Faeth Therapeutics (4070) Stock Statistics & Valuation Metrics
Total Valuation
Faeth Therapeutics has a market cap or net worth of EUR 432.44M. The enterprise value is -EUR 38.00M.
- Market Cap
- EUR 432.44M
- Enterprise Value
- -EUR 38.00M
Share Statistics
Faeth Therapeutics has 25,840,425 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 25,840,425
- Owned by Insiders
- 5.14%
- Owned by Institutions
- 6.51%
Financial Efficiency
Faeth Therapeutics’s return on equity (ROE) is -1.13 and return on invested capital (ROIC) is -110.88%.
- Return on Equity (ROE)
- -1.13
- Return on Assets (ROA)
- -0.92
- Return on Invested Capital (ROIC)
- -110.88%
- Return on Capital Employed (ROCE)
- -1.20
- Revenue Per Employee
- 0
- Profits Per Employee
- -727.07K
- Employee Count
- 29
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Faeth Therapeutics is -0.13. Faeth Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.13
- PS Ratio
- -99.32
- PB Ratio
- 0.61
- Price to FCF
- -14.23
- Price to Operating Cash Flow
- -3.12
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Faeth Therapeutics had revenue of 0 and earned -21.09M in profits. Earnings per share was -16.72.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -22.29M
- Pretax Income
- -21.09M
- Net Income
- -21.09M
- EBITDA
- -20.91M
- Earnings Per Share (EPS)
- -16.72
Cash Flow
In the last 12 months, operating cash flow was -33.86M and capital expenditures -6,000, giving a free cash flow of -33.86M billion.
- Operating Cash Flow
- -33.86M
- Free Cash Flow
- -33.86M
- Free Cash Flow per Share
- -6.00
Dividends & Yields
Faeth Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.03%
- Earnings Yield
- -185.39%
Stock Price Statistics
- Beta
- 0.78
- 52-Week Price Change
- 171.67%
- 50-Day Moving Average
- 25.28
- 200-Day Moving Average
- 11.36
- Relative Strength Index (RSI)
- 35.48
- Average Volume (3m)
- 98
Important Dates
Faeth Therapeutics upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 04, 2026
- Next Earnings Date
- Nov 10, 2026
- Ex-Dividend Date
- ―
Financial Position
Faeth Therapeutics as a current ratio of 5.06, with Debt / Equity ratio of 8.12%
- Current Ratio
- 5.06
- Quick Ratio
- 5.06
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.34
- Interest Coverage Ratio
- -696.50
Taxes
In the past 12 months, Faeth Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Faeth Therapeutics EV to EBITDA ratio is -2.33, with an EV/FCF ratio of -13.45.
- EV to Sales
- -93.90
- EV to EBITDA
- -2.33
- EV to Free Cash Flow
- -13.45
- EV to Operating Cash Flow
- -13.45
Balance Sheet
Faeth Therapeutics has EUR 186.44M in cash and marketable securities with EUR 592.00K in debt, giving a net cash position of EUR 185.85M billion.
- Cash & Marketable Securities
- EUR 186.44M
- Total Debt
- EUR 592.00K
- Net Cash
- EUR 185.85M
- Net Cash Per Share
- EUR 7.19
- Tangible Book Value Per Share
- EUR 30.65
Margins
Gross margin is 2740.82%, with operating margin of 4098.54%, and net profit margin of 4030.69%.
- Gross Margin
- 2740.82%
- Operating Margin
- 4098.54%
- Pretax Margin
- 4030.69%
- Net Profit Margin
- 4030.69%
- EBITDA Margin
- 4027.99%
- EBIT Margin
- 4030.51%
Analyst Forecast
The average price target for Faeth Therapeutics is EUR 51.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 51.56
- Price Target Upside
- 216.32% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -515.67%
Scores
- Smart Score
- 10
- AI Score
- ―
